Valion Bio, Inc. Common Stock (NASDAQ:VBIO) Posts Earnings Results, Beats Estimates By $405.83 EPS

Valion Bio, Inc. Common Stock (NASDAQ:VBIO) posted its quarterly earnings data on Monday. The company reported ($2.17) EPS for the quarter, topping analysts’ consensus estimates of ($408.00) by $405.83, FiscalAI reports.

Valion Bio, Inc. Common Stock Stock Performance

VBIO opened at $0.16 on Wednesday. The stock’s 50 day simple moving average is $0.42 and its 200-day simple moving average is $0.75. The company has a current ratio of 3.31, a quick ratio of 3.02 and a debt-to-equity ratio of 0.62. The stock has a market cap of $666,650.60, a PE ratio of -0.03 and a beta of 1.85. Valion Bio, Inc. Common Stock has a 1 year low of $0.15 and a 1 year high of $3.66.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Valion Bio, Inc. Common Stock in a research report on Friday, July 17th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has an average rating of “Sell”.

About Valion Bio, Inc. Common Stock

Tivic Health Systems is a commercial-stage medical technology company that develops and markets non-drug, neuromodulation-based therapies for nasal and sinus health. The company’s solutions are designed to alleviate sinus pain, pressure and congestion through gentle microcurrent and vibration stimulation. By targeting the underlying nerve pathways in the nasal passages, Tivic Health aims to provide an alternative to over-the-counter and prescription medications without introducing systemic side effects.

The flagship product, ClearUP™ Sinus Pain Relief, is an FDA-cleared, hand-held device intended for home use.